The implementation of the National Health System (NHS), as well as Cypriot patients access to innovative medicines, will be discussed during separate meetings between the Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA), Mr Richard Bergstrom, and the Ministers of Finance and Health on 4 September in Cyprus.
According to an announcement by the Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA), the aim of Mr Bergstrom’s visit is to discuss the NHS with the Finance and Health Ministers, and specifically the integration of medicines in the new health system, taking into account the practices applied in other European states. Ways of improving Cypriot patients’ access to new, effective medicines are also on the agenda for discussion.
EFPIA represents the pharmaceutical industry operating in Europe. It is the voice of 33 European national pharmaceutical industry associations as well as 40 leading companies committed to researching, developing and bringing new medicines to patients that will improve health and the quality of life.
A pharmacist by training, Mr Bergstrom was appointed Director General of EFPIA in March 2011. He has been a member of the EFPIA Board for a number of years, and chairs its Trust Committee and its Task Force on Health Technology Assessment. He is also a Council member of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA).
KEFEA, as a member of EFPIA, represents the research and development pharmaceutical companies in Cyprus.
Get all the latest news and videos in your inbox. Register FREE